{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:19:41Z","timestamp":1785435581915,"version":"3.56.0"},"reference-count":29,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Neuroendocrine neoplasms (NENs) are rare, heterogeneous tumours arising from neuroendocrine cells located throughout the body. The gastrointestinal (GI) tract is the most frequent site of origin, but lesions in unusual locations such as the duodenum, gallbladder and rectum are diagnostically challenging because of their atypical presentation and radiological appearance. This series describes three patients with NENs at uncommon GI sites, highlighting imaging findings, histopathological features and management tailored to the tumour site and grade.\nContribution:\u00a0Although rare, NENs at uncommon GI sites should be included in the differential diagnosis of hypervascular lesions. Accurate diagnosis requires integration of cross-sectional imaging, somatostatin-receptor PET and immunohistochemistry, guiding individualised therapy.<\/jats:p>","DOI":"10.4102\/sajr.v30i1.3455","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:50:57Z","timestamp":1782474657000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroendocrine neoplasms in uncommon gastrointestinal sites: A case series and literature review"],"prefix":"10.4102","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8691-1824","authenticated-orcid":false,"given":"Neha","family":"Chhabra","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bv3zr67","id-type":"ROR","asserted-by":"publisher"}],"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9899-8298","authenticated-orcid":false,"given":"Angie","family":"Garg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bv3zr67","id-type":"ROR","asserted-by":"publisher"}],"name":"Homi Bhabha National Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u2018carcinoid\u2019: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u20133072. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"ref1","unstructured":"WHO Classification of Tumours Editorial Board. Digestive system tumours. 5th ed. Lyon: IARC Press; 2022."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Tsai SD, Chang WC, Hsu HH, et al. Imaging spectrum of pancreatic neuroendocrine tumors. Abdom Imaging. 2015;40(5):1121\u20131130. https:\/\/doi.org\/10.1007\/s00261-014-0322-7","DOI":"10.1007\/s00261-014-0322-7"},{"key":"ref3","unstructured":"Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors. Medicine (Baltimore). 2020;99(36):e21981."},{"key":"ref4","unstructured":"Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Best Pract Res Clin Gastroenterol. 2012;26(6):755\u2013774."},{"key":"ref5","unstructured":"Kaliounji A, Benjelloun H, Rouibaa F, et al. Pancreatic neuroendocrine tumors: A case report and literature review. Cureus. 2023;15(1):e33747."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(07)70410-2","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"ref7","unstructured":"Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment. World J Gastroenterol. 2010;16(37):4581\u20134596."},{"key":"ref8","unstructured":"Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET\/CT clinical impact in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2011;38(3):502\u2013512."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Eltawil KM, Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the pancreas. J Clin Gastroenterol. 2010;44(10):687\u2013695. https:\/\/doi.org\/10.1097\/MCG.0b013e3181d7a6d4","DOI":"10.1097\/MCG.0b013e3181d7a6d4"},{"key":"ref10","unstructured":"Bargotya M, Patel S, Patel K. Histopathological spectrum of neuroendocrine tumors. J Diagn Pathol Oncol. 2020;5(1):1\u20138."},{"key":"ref11","unstructured":"Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of imaging modalities in pancreatic neuroendocrine tumors. Eur J Radiol. 2014;83(6):1061\u20131068."},{"key":"ref12","unstructured":"Pavithran K, Doval DC, Sharma A, et al. Pancreatic neuroendocrine tumors: An Indian experience. Indian J Med Paediatr Oncol. 2019;40(2):265\u2013268."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Weinstock B, Ward SC, Harpaz N, et al. Clinical and pathological features of pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;98(3):180\u2013187. https:\/\/doi.org\/10.1159\/000355612","DOI":"10.1159\/000355612"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms. Mod Pathol. 2018;31(12):1770\u20131786. https:\/\/doi.org\/10.1038\/s41379-018-0110-y","DOI":"10.1038\/s41379-018-0110-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors. Arch Pathol Lab Med. 2010;134(1):72\u201382. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ec124e","DOI":"10.1097\/MPA.0b013e3181ec124e"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind study on the effect of octreotide LAR in patients with metastatic neuroendocrine midgut tumors. J Clin Oncol. 2009;27(28):4656\u20134663. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms. Neuroendocrinology. 2012;95(2):154\u2013171. https:\/\/doi.org\/10.1159\/000335597","DOI":"10.1159\/000335597"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors. JAMA Oncol. 2017;3(10):1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"ref19","unstructured":"Haug AR, Auernhammer CJ, Wangler B, et al. Intraindividual comparison of 68Ga-DOTATATE and 18F-FDG PET in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2014;41(2):210\u2013219."},{"key":"ref20","unstructured":"Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Am J Surg Pathol. 2020;44(1):113\u2013123."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","DOI":"10.1007\/s12022-022-09708-2"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u2013233. https:\/\/doi.org\/10.1056\/NEJMoa1316158","DOI":"10.1056\/NEJMoa1316158"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Chan DL, Pavlakis N, Schembri GP, et al. Dual 68Ga-DOTATATE and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine neoplasms: Multicentre validation of the NETPET score. Br J Cancer. 2023;128:549\u2013555. https:\/\/doi.org\/10.1038\/s41416-022-02061-5","DOI":"10.1038\/s41416-022-02061-5"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms. Exp Ther Med. 2021;22(6):1479. https:\/\/doi.org\/10.3892\/etm.2021.10914","DOI":"10.3892\/etm.2021.10914"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. J Clin Oncol. 2017;35(14):1695\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1607427","DOI":"10.1056\/NEJMoa1607427"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Tan B, Zhang B, Chen H. Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment. Front Endocrinol (Lausanne). 2024 Sep 30;15:1424839. Available from: https:\/\/doi.org\/10.3389\/fendo.2024.1424839","DOI":"10.3389\/fendo.2024.1424839"},{"key":"ref27","unstructured":"S\u00f8rensen JB, Olsen IH, Lassen U, et al. Treatment of neuroendocrine carcinomas. Cancer Treat Rev. 2013;39(5):505\u2013512."},{"key":"ref28","unstructured":"Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of pancreatic neuroendocrine tumors. Pancreas. 2020;49(10):1262\u20131270."}],"container-title":["South African Journal of Radiology"],"original-title":[],"link":[{"URL":"https:\/\/sajr.org.za\/index.php\/sajr\/article\/view\/3455\/4075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:51:43Z","timestamp":1782474703000},"score":1,"resource":{"primary":{"URL":"https:\/\/sajr.org.za\/index.php\/sajr\/article\/view\/3455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/sajr.v30i1.3455","relation":{},"ISSN":["1027-202X","2078-6778"],"issn-type":[{"value":"1027-202X","type":"print"},{"value":"2078-6778","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"a3455"}}